269 related articles for article (PubMed ID: 31897341)
1. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer.
Cavaliere A; Merz V; Casalino S; Zecchetto C; Simionato F; Salt HL; Contarelli S; Santoro R; Melisi D
J Gastric Cancer; 2019 Dec; 19(4):375-392. PubMed ID: 31897341
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
4. Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
Wöll E; Amann A; Eisterer W; Gerger A; Grünberger B; Rumpold H; Weiss L; Winder T; Greil R; Prager GW
Anticancer Res; 2023 Jul; 43(7):2889-2897. PubMed ID: 37351962
[TBL] [Abstract][Full Text] [Related]
5. Current treatment and recent progress in gastric cancer.
Joshi SS; Badgwell BD
CA Cancer J Clin; 2021 May; 71(3):264-279. PubMed ID: 33592120
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma.
Dhakras P; Uboha N; Horner V; Reinig E; Matkowskyj KA
Transl Gastroenterol Hepatol; 2020; 5():55. PubMed ID: 33073050
[TBL] [Abstract][Full Text] [Related]
7. Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination.
Rha SY; Chung HC
J Gastric Cancer; 2023 Jan; 23(1):224-249. PubMed ID: 36751001
[TBL] [Abstract][Full Text] [Related]
8. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.
Kelly CM; Janjigian YY
J Gastrointest Oncol; 2016 Oct; 7(5):750-762. PubMed ID: 27747089
[TBL] [Abstract][Full Text] [Related]
9. HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives.
Li W; Zhang X; Du Y; Zhang Y; Lu J; Hu W; Zhao J
Biomark Res; 2022 Sep; 10(1):71. PubMed ID: 36175985
[TBL] [Abstract][Full Text] [Related]
10. Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives.
Sato Y; Okamoto K; Kawaguchi T; Nakamura F; Miyamoto H; Takayama T
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884916
[TBL] [Abstract][Full Text] [Related]
11. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
12. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V; Mangiameli D; Zecchetto C; Quinzii A; Pietrobono S; Messina C; Casalino S; Gaule M; Pesoni C; Vitale P; Trentin C; Frisinghelli M; Caffo O; Melisi D
Front Surg; 2022; 9():866173. PubMed ID: 35599791
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
14. The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer.
Koerner AS; Moy RH; Ryeom SW; Yoon SS
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627142
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.
Piro G; Carbone C; Santoro R; Tortora G; Melisi D
Expert Rev Mol Diagn; 2018 Apr; 18(4):357-370. PubMed ID: 29544370
[TBL] [Abstract][Full Text] [Related]
16. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.
Sato Y; Okamoto K; Kawano Y; Kasai A; Kawaguchi T; Sagawa T; Sogabe M; Miyamoto H; Takayama T
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510761
[TBL] [Abstract][Full Text] [Related]
17. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
19. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study.
Zhou M; Yang W; Xuan Y; Zou W; Wang Y; Zhang Z; Zhang J; Mo M; Zhou C; Liu Y; Zhang W; Zhang Z; He Y; Weng W; Tan C; Wang L; Huang D; Sheng W; Li H; Zhu H; Wang Y; Shen L; Zhang H; Wan J; Li G; Huang H; Wang Y; Zhang Z; Liu X; Xia F
BMC Cancer; 2022 Jun; 22(1):710. PubMed ID: 35764956
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
